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Abstract Whilst the human body expends energy constantly, the human diet consists
of a mix of carbohydrates and fats delivered in a discontinuous manner. To deal with
this sporadic supply of energy, there are transport, storage and utilisation mechanisms,
for both carbohydrates and fats, around all tissues of the body. Insulin-resistant states
such as type 2 diabetes and obesity are characterised by reduced efficiency of these
mechanisms. Exactly how these insulin-resistant states develop, for example whether
there is an order in which tissues become insulin resistant, is an active area of research
with the hope of gaining a better overall understanding of insulin resistance. In this
paper, we use a previously derived system of 12 first-order coupled differential equa-
tions that describe the transport between, and storage in, different tissues of the human
body. We briefly revisit the derivation of the model before parametrising the model to
account for insulin resistance. We then solve the model numerically, separately simu-
lating each individual tissue as insulin resistant, and discuss and compare these results,
drawing three main conclusions. The implications of these results are in accordance
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with biological intuition. First, insulin resistance in a tissue creates a knock-on effect
on the other tissues in the body, whereby they attempt to compensate for the reduced
efficiency of the insulin-resistant tissue. Second, insulin resistance causes a fatty liver,
and the insulin resistance of tissues other than the liver can cause fat to accumulate in
the liver. Finally, although insulin resistance in individual tissues can cause slightly
reduced skeletal muscle metabolic flexibility, it is when the whole body is insulin
resistant that the biggest effect on skeletal muscle flexibility is seen.
Keywords Multicompartmental modelling · Metabolic flexibility · Insulin resistance
1 Introduction
Whilst the human body expends energy constantly, the human diet consists of a mix of
carbohydrates and fats delivered in a discontinuousmanner. To deal with this sporadic
supply of energy, there are transport, storage and utilisation mechanisms, for both
carbohydrates and fats, around various tissues in the body.
The skeletal muscle of healthy lean subjects is able to switch its fuel source between
mainly carbohydrates in the insulin-stimulated postprandial state to predominantly fats
in the fasted state. The main regulatory hormone involved in metabolism is insulin,
and hence, insulin-resistant states such as obesity and type 2 diabetes are characterised
by a reduction in metabolic flexibility (Kelley and Mandarino 2000; Kelley 2005).
There are three broad categories of insulin-resistance or insulin-deficient states: (i)
abnormal β-cell secretory product, which results in reduced insulin production in the
pancreas; (ii) insulin antagonists in the blood plasma, due either to counterregulatory
hormones or to non-hormonal bodies that affect insulin receptors or alter insulin-
signalling effectiveness; (iii) the target tissue being defective in insulin action, due to
defects either in the insulin receptors or to the effector systems. The third of these is of
most interest here, since this form of insulin resistance is common in some obese and
all type 2 diabetic subjects, although early-phase insulin secretion is also inhibited
in some type 2 diabetic subjects (Olefsky 1981; Mizuno et al. 2007). Both obese
and diabetic subjects exhibit lower plasma glucose disposal rates and increased basal
glucose levels (Olefsky 1981; Mizuno et al. 2007; Prager et al. 1986).
In type 2 diabetes these effects are partly explained by impaired hepatic glucose
uptake (Mizuno et al. 2007; Iozzo et al. 2003) and a reduction in the suppression
of hepatic glucose output by insulin (Kotronen et al. 2008). Also, skeletal muscle
glucose uptake is impaired in type 2 diabetes (Phielix and Mensink 2008). In non-
diabetic obese subjects, there is reduced skeletalmuscle glucose uptake (denBoer et al.
2006) and reduced hepatic glucose output suppression from insulin (Olefsky 1981;
Prager et al. 1986). Furthermore, insulin-resistant subjects may experience increased
hepatic lipogenesis, leading to larger changes in hepatic triglyceride concentrations
in the postprandial state, a counterintuitive result since it is an insulin-stimulated
pathway. The reason for this effect is that the blood supply from the pancreas goes
directly to the liver, and the initial response to insulin resistance is increased insulin
secretion. However, Peterson et al. (2007) have shown that insulin-resistant subjects
have a significantly larger reduction in muscle glucose uptake, indicating that insulin
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resistance affects different tissues to different degrees (Peterson et al. 2007), the liver
being less severely affected, as noted by Bock et al. (2007).
Not only does insulin resistance affect glucose metabolism, it also affects adipose
tissue, which exhibits a reduced insulin suppression of free fatty acid release (den Boer
et al. 2006). Insulin-resistant subjects also suffer from reduced clearance of adipose
tissue triglyceride and lower skeletal muscle triglyceride clearance (Bickerton et al.
2008). Currently, fatty liver disease is a major area of interest as it relates to insulin
resistance and obesity. It is not currently knownwhether obesity causes or is caused by
fatty liver disease or whether both are the cause of some other process (Rijkelijkhuizen
et al. 2009). It has been shown that postprandial hepatic triglyceride release is higher
in people with fatty liver disease than healthy people, although the basal secretion
rate is the same. This result implies that it is not a higher fat presence in the liver that
causes the increased output, but rather insulin resistance (Adiels et al. 2007).
In this paper, we use amathematical model whichwas derived in detail in a previous
paper Pearson et al. (2014) to simulate insulin resistance. In Sect. 2.1, we briefly recap
the model, and in “Appendix 1”, we use experimental data available from the literature
to parametrise insulin resistance in various tissues of the body.
The model neglects protein metabolism, since those processes are largely separate,
and would vastly complicate the model were they to be included. Carbohydrate and
fat metabolism have more significant interactions and can be modelled in a useful way
relatively simply. The results of simulations of such models aid our understanding
of metabolism in the body as a whole. Our models are kept as simple as possible by
neglecting another feature present in the early onset of insulin resistance: namely, that
the pancreas will supply higher levels of insulin to counterbalance small and moderate
levels of insulin resistance in other tissues. Our first aim is to isolate the effects of
insulin resistance in other tissues. In the later works Pratt et al. (2015b), Pratt (2015),
we plan to include terms to model the glucose sensitivity of insulin production by the
pancreas.
The remainder of Sect. 2 discusses each tissue in turn, and its response to glucose,
fatty acids and TAG. In Sect. 3, we compare the results of simulations of insulin-
resistant subjects and healthy subjects. We first simulate the case of each individual
tissue in our model (liver, skeletal muscle and adipose tissue) being insulin resistant
whilst the other tissues are normal; later, we consider whole-body insulin resistance.
Our motivation for this approach is to investigate the effect of insulin resistance of
an individual tissue on whole-body metabolism, in order to provide some insight into
the order in which tissues may become insulin resistant in the development of type 2
diabetes. In Sect. 4, we summarise our results and draw conclusions, as well as discuss
possible directions for future work.
2 Mathematical Model
2.1 Preliminaries
The mathematical model we use in this paper was derived in detail in an earlier paper
(Pearson et al. 2014). In this section, we briefly recap the model whilst generalising
it to encompass insulin resistance. The model is multicompartmental in nature and
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Fig. 1 Diagram of the biochemical reaction network used in this paper.Dashed boxes indicate the different
compartments of the model with the liver at the top, the blood plasma in the middle and skeletal muscle at
the bottom. glu glucose, gly glycogen
describes the concentrations of glucose, fatty acids, TAG, glycogen and insulin in the
various main tissues of the human body involved in metabolism. We include skeletal
muscle, the liver, adipose tissue [as a supply of free fatty acids (FFAs) and sink for
triglycerides (TAGs)] and the blood plasma, which acts as a transportation medium
between the tissues. The relevant metabolic pathways are shown in Fig. 1.
As indicated in Fig. 1, the pathways we model are: the uptake of glucose from the
blood into the liver with rate kL (and release back into the blood with rate βG ) and
skeletal muscle (kG), the uptake of TAG from the blood into adipose tissue (kT A) and
skeletal muscle (kT ) as well as the release into the blood from the liver (βT ); and the
uptake of FFA from the blood into the liver (kBL ) and skeletal muscle (kA), as well as
release into the blood from the liver (kLB) and adipose tissue (βA). In addition to these
transport pathways via the blood plasma, we model some of the metabolic pathways
within the liver and skeletal muscle. In the liver, some glucose is converted to glycogen
for storage (kL ) and later release (βG ); in addition, some glucose is converted into FFA
via glycolytic and lipogenesis pathways (kAL )—this hepatic FFA can be released back
into the plasma (kLB) or converted into TAG in the liver (kT H ) to be stored and released
later when the body needs it (βT ).
When TAG from the plasma is taken up into either adipose tissue or skeletal muscle,
it is first broken down into FFA on the cell walls by the enzyme lipoprotein lipase.
Hence, the uptake of both FFA and TAG from the plasma contributes to skeletal muscle
FFA. The FFA in skeletal muscle can either be stored as TAG in the muscle or oxidised
to form adenosine triphosphate (ATP). Similarly to the uptake of fats, glucose is also
taken up into skeletal muscle, where it can either be stored as glycogen or oxidised to
form ATP.
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Table 1 Dimensional variables
with their descriptions
Variable Concentration of:
I Plasma insulin
Gb Plasma glucose
Tb Plasma TAG
Ab Plasma FFA
YL Hepatic glycogen
AL Hepatic FFA
TL Hepatic TAG
P Skeletal muscle AMP
Gm Skeletal muscle glucose
Ym Skeletal muscle glycogen
Am Skeletal muscle FFA
Tm Skeletal muscle TAG
In addition to the pathways shown in Fig. 1 the model also includes source terms
in the form of time-dependent functions modelling input of glucose, FFA and TAG
from the diet into the blood, via the terms FG, FT , and sink terms including the use
of substrates from the plasma by the rest of the body, SG , and the oxidation of FFA in
the liver for energy, SL .
We model the concentration of insulin in the plasma by assuming a produc-
tion term with nonlinear dependence on glucose given by f0(Gb), see (2), and a
smaller linear dependence on FFA in the plasma, with constant of proportionality
kI A. This latter term (kI A Ab) is small in comparison with the glucose-dependent
term ( f0), and in our simulations meals are combinations of carbohydrates and fatty
acids. The model is described by the variables listed in Table1, and the rate para-
meters are summarised in Table2, the kinetics being expressed in the following
equations that comprise the dimensionless model (see Pearson et al. 2014 for the non-
dimensionalisation):
dI
dt
= f0(Gb) + kI A Ab − λI I, (1)
f0(Gb) = k1 + k2erf((Gb − v)/c), (2)
α
dGb
dt
=
(
βG
1 + σLkGL I 2
)
f1(YL) − SGGb
−kG(1 + σGkGI I )Gb − kLσY IGb f2(YL) − kAL IGb + FG(t), (3)
α
dTb
dt
=
(
βT
1 + σT kT L I
)
f3(TL) − kT Tb − φAT kT A(1 + σAT kAI I )Tb + FT (t),
(4)
α
dAb
dt
= φAβA
1 + σAkAA I 2 − kA Ab − kBL Ab + kLB AL , (5)
η
dYL
dt
= kLσY IGb f2(YL) −
(
βG
1 + σLkGL I 2
)
f1(YL), (6)
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Table 2 List of dimensional parameters together with brief description of each
Parameter Description Value
MG Glucose oxidation rate
MA FFA oxidation rate
kY Glycogen synthesis rate (basal)
kY I Glycogen synthesis rate (insulin stimulated)
kY P Glycogen synthesis rate (AMP inhibited)
kT Muscle triglyceride uptake rate (basal) 2 × 10−4 mmol/l/min
kG Muscle glucose uptake rate (basal) 3.6 × 10−3 mmol/l/min
kGI Muscle glucose uptake rate (insulin
stimulated)
1.75 × 107 l/mmol
kCP Glycogenolysis rate (AMP stimulated)
kC I Glycogenolysis rate (insulin inhibited) 0
SG Body glucose consumption rate
μ AMP (P) creation rate
λI Insulin degradation rate
k1 Insulin production rate 6.97 × 10−5 mmol/min
k2 Insulin production rate 8.36 × 10−5 mmol / min
kIG Insulin production rate
kI2 Insulin production rate
kI A Insulin production rate
kA Muscle FFA uptake rate constant
βA Basal FFA production rate 0.011 mmol/l/min
βT Basal triglyceride production rate 2.25 × 10−4 mmol/l/min
βG Basal glucose production rate 0.019mmol/l/min
α Plasma volume/skeletal muscle volume 0.17
γa Number of P molecules used in FFA
oxidation
γg Number of P molecules used in glucose
oxidation
λP Degradation of P in the absence of any other
process
kGL Insulin inhibition rate of glucose from liver 1.06 × 1014 l2/pmol2
kT L Insulin inhibition rate of TAG from liver 2.5 × 106 l/mmol
kAA Insulin inhibition rate of FFA from adipose
tissue
2 × 1014 l2/pmol2
kT A Adipose TAG uptake const (basal) 0.5 × 10−4 min−1
kAI Adipose TAG uptake const (insulin
stimulated)
5 × 106 l/mmol
kX Muscle TAG synthesis rate const (basal)
kX I Muscle TAG synthesis const (insulin
stimulated)
0
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Table 2 continued
Parameter Description Value
kX P Muscle TAG synthesis const (AMP inhibited) 0
kDP Muscle TAG usage const (AMP stimulated)
kDI Muscle TAG usage const (insulin inhibited) 0
kL Liver glucose uptake rate 2 × 104 l/mmol/min
Ymax Maximum potential glucose stored in liver 310 mmol/l
η Liver volume/skeletal muscle volume 0.064
kAL Rate of conversion of glucose to FFA (glycolysis)
kAS Insulin inhibition rate of hepatic FFA oxidation
kBL Rate of uptake of plasma FFA into the liver
kLB Rate of release of hepatic FFA into blood plasma
kT H Rate of conversion of FFA to TAG in the liver
SL Rate of oxidation of FFA in the liver
BT Delay from feeding to triglyceride reaching blood
BG Delay from feeding to glucose reaching blood
kFG Rate of uptake of glucose to blood
kFT Rate of uptake of triglyceride to blood
θG Proportion of carbohydrates in diet
θT Proportion of triglyceride in diet
F Total calorific content of diet
Values of zero correspond to processes which are straightforward to include in the model, but are less
significant and harder to parametrise, so for simplicity, we set their values to zero
η
dAL
dt
= kAL IGb − SL AL
1 + kAS I + kBL Ab − kLB AL − kT H I AL , (7)
η
dTL
dt
= kT H I AL −
(
βT
1 + σT kT L I
)
f3(TL), (8)
dP
dt
= μ − λP P − γaMA Am P − σGγgMG P IGm, (9)
dGm
dt
= kG(1 + σGkGI I )Gb − σG MG P IGm − kY
(
1 + σGkY I I
1 + kY P P
)
Gm
+ kCP PYm
1 + σGkC I I , (10)
dYm
dt
= kY
(
1 + σGkY I I
1 + kY P P
)
Gm − kCP PYm
1 + σGkC I I , (11)
dAm
dt
= kT Tb + kA Ab − MAP Am − kX
(
1 + kX I I
1 + kX P P
)
Am + kDP PTm
1 + kDI I , (12)
dTm
dt
= kX
(
1 + kX I I
1 + kX P P
)
Am − kDP PTm
1 + kDI I . (13)
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Table 3 Dimensionless insulin sensitivity (resistance) parameters, togetherwith their values and references
from which their values are inferred
Parameter Description Value References
σY Hepatic glucose uptake sensitivity 0.5 Krssak et al. (2004)
σL Hepatic glucose output sensitivity 0.06 Krssak et al. (2004)
σT Hepatic TAG output sensitivity 0.25 Adiels et al. (2007)
σA = σAT Adipose tissue FFA output & TAG
uptake sensitivity
0.1 Bickerton et al. (2008)
φA = φAT Adipose tissue FFA output & TAG
uptake sensitivity
0.4 Bickerton et al. (2008)
σG Skeletal muscle glucose uptake
sensitivity
0.2 Basu et al. (2007)
Details of this procedure are given in “Appendix 1”
The source terms FG(t) and FT (t) are given by
FG(t) = FθGt
B2G
e−t2/2B2G , FT (t) = FθT t
B2T
e−t2/2B2T , (14)
respectively, representing glucose and TAG inputs from the diet, and the functions
f1(YL), f2(YL) and f3(YL) by
f1(YL) = YL
Y0 + YL , f2(YL) =
Ymax − YL
Y0 + Ymax − YL , f3(TL) =
TL
T0 + TL . (15)
Note that the model given in Eqs. (1)–(15) is a generalisation of the one derived in
Pearson et al. (2014), in that additional parameters σY , σL , σT , σA, σG , φA have been
introduced tomodel insulin sensitivity. The derivation of values for these parameters is
discussed in the next section. Their values are summarised in Table3, whilst Tables1
and 2 contain a summary of the variables used in the model and a detailed list of
parameters, respectively.
3 Numerical Results
In this section, we use the model to explore the effects of insulin resistance on the
various tissues of the body and the resultant effects on the other tissues. We produce
results for the case of each individual tissue being insulin resistant, and the case where
all tissues are resistant, and compare these results against simulations of the control
casewhere no tissues are resistant.All simulations correspond to initial conditions of an
overnight fast followed by ingestion of a healthy balanced meal containing 550 kcal of
carbohydrates (glucose) and 150 kcal of fats (TAG). For the numerical solution, we use
a quadratic approximation to the insulin production term, f0(Gb) = kIGGb + kI2G2b.
The equations are solved in their non-dimensional form, all concentrations having
been scaled by their postprandial steady-state values, so that all the corresponding
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Fig. 2 Postprandial kinetics for plasma glucose (top left), plasma insulin (bottom left), plasma TAG (top
right) and plasma FFA (bottom right) for a balanced meal; the response of a healthy subject is indicated by
the dashed line and the case of insulin-resistant adipose tissue by the solid lines
non-dimensional concentrations are unity. This state is used as the initial conditions
for a numerical solution of the system.
The control case of no insulin resistance was studied in Pearson et al. (2014).
The results for this case are illustrated by the dashed lines in Figs. 2, 3, 4 and 5.
Figure 2 shows that the ingestion of the meal causes a spike in plasma glucose which,
in turn, causes an increase in insulin, a reduction in plasma FFA and an increase in
plasma TAG over a longer timescale. These increases in glucose and TAG are taken
up by the liver and muscle, as shown in Figs. 3 and 4, where liver glycogen and TAG
increases; similar behaviour is seen in muscle glucose and glycogen. The reduction
in FFA is also seen in the liver and muscle, with muscle TAG also experiencing a
reduction, due to the interconversion between FFA and TAG in the muscle. Figure 5
shows an increase in adipose tissue TAGclearance and reduction inAMP as themuscle
switches to aFFA-glucose balance of energy usage tomore heavily rely on the available
glucose.
In the following sections, we consider the cases where each individual tissue is
insulin resistant whilst the rest of the body has normal sensitivity. Finally, in Sect. 3.4,
we discuss the case where all tissues are insulin resistant. For completeness, the cases
in which two of the three tissues are insulin resistant whilst the third has normal
sensitivity is discussed in “Appendix 2”. Whilst we acknowledge that such cases may
not be as relevant physiologically, we include them for the sake of presenting a full
analysis of the mathematical model.
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Fig. 3 Postprandial kinetics for hepatic glycogen (top left), hepatic FFA (top right), hepatic TAG (bottom)
for a balanced meal (14); the response of a healthy subject is shown by the dashed lines and the case of
insulin-resistant adipose tissue by the solid
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Fig. 4 Postprandial kinetics for muscle glucose (top left), muscle glycogen (bottom left), muscle FFA (top
right) and muscle TAG (bottom right) for a balanced meal. The dashed line shows the response of a healthy
subject and the solid line the response of insulin-resistant adipose tissue
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Fig. 5 Postprandial kinetics for fractional glucose oxidation (top left), adipose tissue TAG clearance (top
right) and P , our AMP marker (bottom left), for a balanced meal. The response of a healthy subject is
shown by a dashed line and that of insulin-resistant adipose tissue by a solid line
3.1 The Case Where Only Adipose Tissue is Insulin Resistant
We first discuss the results for plasma concentrations when only adipose tissue is
insulin resistant, which are shown in Fig. 2. In this case we solve the system (1)–
(15) with all the σX (X = A, AT, G, L , T,Y ) parameters set to unity, except for
σA = σAT = 0.1 and φA = φAT = 0.4 as given in Table3. The results for plasma
glucose and insulin are indistinguishable to those for a healthy individual with no
tissues insulin resistant. However, the results for plasma TAG and FFA show some
differences. The baseline level of plasma FFA is lower in the insulin-resistant case.
Following ingestion of a meal, plasma FFA levels still decrease for insulin-resistant
adipose tissue, but by a much smaller amount than in the control. Also, plasma TAG
is seen to rise to a slightly higher level following the meal.
We now turn to the liver concentrations shown in Fig. 3. These results show that
hepatic glycogen storage is almost indistinguishable from that of a healthy subject.
However, hepatic FFA levels are higher in individuals with insulin-resistant adipose
tissue, which has the effect of increasing hepatic TAG content as well as leading to
a net gain in hepatic TAG content. This increase in hepatic FFA, and subsequently
TAG, is due to the increased plasma FFA levels following the meal caused by insulin
resistance in the pathway for adipose tissue FFA output.
In Fig. 4 we show the muscle concentrations of glucose, glycogen, FFA and TAG.
Following the meal, muscle glucose and glycogen levels are indistinguishable from
healthy subjects (Fig. 4, upper and lower left panels). As with plasma, the fasting
level of FFA in muscle is lower in the insulin-resistant case than in the healthy. The
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muscle FFA and TAG response to the meal, however, show that, although there is still
an initial decline in muscle concentrations, it is less than in healthy individuals, and
subjects with insulin-resistant adipose tissue subsequently exceed their steady-state
values during the recovery phase, showing that there is an increased uptake of fat into
skeletal muscle when adipose tissue is insulin resistant.
The results for our measure of metabolic flexibility, namely fractional glucose
oxidation, together with P , our proxy for AMP concentration in muscle, and adipose
tissue TAG clearance are shown in Fig. 5. These results show a slightly reduced
metabolic flexibility when compared to those for a healthy individual, and adipose
TAGclearance is reduced significantly in subjectswith insulin-resistant adipose tissue.
This clarifies why following ingestion of a meal the predicted plasma TAG level is
higher than that of healthy individuals.
3.2 The Case Where Only the Liver is Insulin Resistant
For this case, we take σG = σY = 1 and φA = φAT = 1 and set σL , σY and σT
to the values given in Table3. We discuss the results in the same order as in the
previous section, first considering the plasma concentrations shown in Fig. 6. The
insulin-resistant liver is broadly similar to that of a healthy individual; however, there
is a slight increase in plasma glucose and insulin levels due to the liver not taking up
as much glucose.
The liver concentrations are shown in Fig. 7. Hepatic FFA levels are similar to
those of a healthy individual due to the transport between plasma and the liver of FFA
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Fig. 6 Postprandial kinetics for plasma glucose (top left), plasma insulin (bottom left), plasma TAG (top
right) and plasma FFA (bottom right) for a balanced meal; the dashed line shows the response of a healthy
subject and the solid line the case where the liver is insulin resistant
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Fig. 7 Postprandial kinetics for hepatic glycogen (top left), hepatic FFA (top right), hepatic TAG (bottom)
for a balanced meal; the response of a healthy subject is shown by the dashed line and that of an insulin-
resistant liver by a solid line
being independent of insulin. Following the meal less glycogen and TAG are stored
in the liver which result in a net reduction of both in the liver. From Figs. 8 and 9 this,
instead, goes into muscle glucose, and glycogen, and adipose tissue, respectively. In
the insulin-resistant liver, the hepatic concentration of glycogen is significantly lower
than that for a healthy individual.
Figure 8 shows themuscle concentrations of glucose, glycogen, FFAandTAGwhen
the liver is insulin resistant. We observe that muscle TAG and FFA are not affected
by hepatic insulin resistance. Following ingestion of the meal, muscle glucose and
glycogen levels rise to a slightly higher level than those of a healthy individual due to
an increased muscle glucose uptake which partly compensates for the inability of the
insulin-resistant liver to take up plasma glucose. Increased muscle glucose causes a
slightly larger reduction in the muscle concentration of P shown in Fig. 9, and there
is no significant difference in the fraction of oxidation due to glucose.
3.3 The Case Where Only Skeletal Muscle is Insulin Resistant
The case of insulin-resistant skeletal muscle produces the most interesting results. We
set all σX and φZ variables to unity (X = AT, G, L , T,Y, Z = A, AT ), with the
sole exception of σG , which is set at 0.15, as given in Table3 and derived in “Skeletal
Muscle Glucose Uptake” section in “Appendix 1”. Again, we start with the plasma
concentrations, which are presented in Fig. 10. We clearly see that postprandial glu-
cose and insulin levels are higher than in healthy individuals and they also exhibit a
strange double spike which affects other concentrations as insulin is the main regula-
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Fig. 8 Postprandial kinetics for muscle glucose (top left), muscle glycogen (bottom left), muscle FFA (top
right) and muscle TAG (bottom right) for a balanced meal; the response of a healthy subject is shown by
the dashed line and that of an insulin-resistant liver by the solid line
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Fig. 9 Postprandial kinetics for factional glucose oxidation (top left), adipose tissue TAG clearance (top
right) and P , our AMP marker (lower left), for a balanced meal; the response of a healthy subject is shown
by the dashed line and that of an insulin-resistant liver by a solid line
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Fig. 10 Postprandial kinetics for plasma glucose (top left), plasma insulin (bottom left), plasma TAG (top
right) and plasma FFA (lower right) for a balanced meal; the response of a healthy subject is shown by the
dashed line and that of insulin-resistant skeletal muscle by a solid line
tory hormone formany pathways in ourmodel. This double spike is noticeable because
we have plotted the solutions of our differential equations as continuous curves, and
if a sequence of points had been shown, it would not be noticeable. The reason for
the double spike is the liver glycogen store having a fixed maximum capacity, which
suddenly alters the nature of the equations when it is filled; in reality this effect would
be smoothed out. The raised insulin levels cause a reduction in plasma TAG and an
extended period of reduced FFA concentrations.
The liver concentrations shown in Fig. 11 explain the unusual results in the blood
plasma. Following ingestion of the meal the liver becomes saturated in glycogen and
is unable to clear excess glucose from the plasma. This leads to the second spike in
plasma glucose and insulin. We observe a net gain in liver TAG content caused by an
increase in hepatic FFA at earlier times, of 0 < t < 3, which corresponds to 3h.
Turning to Fig. 12, we note that muscle FFA and TAG concentrations drop to lower
levels, before recovering their steady- state values, this occurring on a similar timescale
to that for normal subjects. Thus in the muscle, insulin resistance has the major
effect on carbohydrate processes and only a minor effect on mechanisms involving
fats.
The percentage of glucose oxidation, themuscle concentration of P and the adipose
TAG clearance are shown in Fig. 13. From Fig. 12 we note that muscle glucose and
glycogen levels rise to similar values as in healthy individuals, despite reduced plasma
glucose uptake. However, both glucose and glycogen take much longer to return to
steady-state levels. This is due to the lower rate of glucose oxidation occurring in
the muscle. The results initially show a lower percentage of glucose oxidation than
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Fig. 11 Postprandial kinetics for hepatic glycogen (top left), hepatic FFA (top right), hepatic TAG (bottom)
for a balanced meal; the response of a healthy subject is indicated by the dashed line and that of insulin-
resistant skeletal muscle by a solid line
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Fig. 12 Postprandial kinetics for muscle glucose (top left), muscle glycogen (bottom left), muscle FFA
(top right) and muscle TAG (bottom right) for a balanced meal; the dashed lines show the response of a
healthy subject and the solid lines, the case of insulin-resistant skeletal muscle
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Fig. 13 Postprandial kinetics for fractional glucose oxidation (top left), adipose tissue TAG clearance (top
right), P our AMPmarker (lower left) for a balanced meal. The dashed lines show the response of a healthy
subject, and the case of insulin-resistant skeletal muscle is shown by a solid line
in healthy individuals; however, this ratio still reaches a similar peak postprandially
due to insulin levels being much higher in the insulin-resistant muscle and the amount
of FFA available for oxidation in the muscle also being reduced. This explanation is
supported by our results for P , which imply less total oxidation occurring in the mus-
cle. The graph of fractional glucose oxidation surprisingly shows that the metabolic
flexibility; that is, the range of fractional oxidation is smaller for the IR cases than the
healthy. Our results show a decrease in adipose TAG clearance over that for healthy
individuals.
3.4 The Case Where All Tissues Are Insulin Resistant
We now solve the model with all tissues insulin resistant, that is, when all σX and φZ
parameters (X = A, AT, L , G,Y, T , Z = A, AT ) take the values given in Table3.
We first describe the results for plasma concentrations shown in Fig. 14. Following
the meal, plasma glucose, TAG and insulin all rise to higher levels than in a healthy
individual, whilst plasma FFA is suppressed to a lesser extent. The plasma levels in
this simulation are higher than when any one tissue is insulin resistant. This increased
effect is caused by a greater total reduction in plasma glucose clearance due to every
tissue being insulin resistant.
FromFig. 14we observe that in the insulin-resistant case, the fasting level of plasma
TAG is higher than in the healthy state. This is typically expected and supports the
suggestion of McLaughlin et al. (2003) that fasting plasma TAG could be used as an
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Fig. 14 Postprandial kinetics for plasma glucose (top left), plasma insulin (bottom left), plasma TAG (top
right) and plasma FFA (bottom right) for a balanced meal. The dashed line shows the response of a healthy
subject and the solid line the case where all tissues are insulin resistant
indicator of insulin resistance. We note that this is not the case when only muscle is
resistant (Fig. 10), is a small effect when adipose tissue is resistant (Fig. 2), and a
slightly larger effect when liver is resistant (Fig. 6).
The liver concentrations are shown in Fig. 15. Hepatic glycogen behaves similarly
in the healthy individual to the case where all tissues are insulin resistant. This is due to
the plasma glucose and insulin levels being higher in the insulin-resistant case, which
counteracts the reductions in uptake and release rates caused by the insulin resistance,
and leads to similar fluxes. Following the meal, hepatic FFA shows a much smaller
suppression in the case where all tissues are insulin resistant. However, hepatic TAG
exhibits a significant net gain following the meal which, as we shall see below, is due
to insulin resistance suppressing TAG take-up by adipose tissue, leaving plasma TAG
levels elevated for an extended period of time.
Figure 16 shows thatmuscle glucose and glycogen rise to similar levels as in healthy
subjects, due to the increased plasma glucose; however, they take much longer to
return to their steady states compared to healthy individuals. This slow behaviour is
due to glucose oxidation being insulin stimulated. These results when all tissues are
insulin resistant are similar to those for the case where only muscle is insulin resistant,
and again, insulin resistance lowers the fasting levels of FFA in the muscle tissue.
The timescales for muscle TAG and FFA equilibrium are similar to those for healthy
individuals, although we see a smaller suppression following the meal, due to the
increased postprandial plasmaFFAbeing takenup into themuscle tissue independently
of insulin. The timescale over which muscle FFA and muscle TAG return to steady
state is unaffected by insulin resistance.
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Fig. 15 Postprandial kinetics for hepatic glycogen (top left), hepatic FFA (top right), hepatic TAG (bottom)
for a balanced meal. The results for a healthy subject are indicated by the dashed lines, and the solid line
shows the case where all tissues are insulin resistant
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Fig. 16 Postprandial kinetics for muscle glucose (top left), muscle glycogen (bottom left), muscle FFA
(top right) and muscle TAG (bottom right) for a balanced meal. The response of a healthy subject is shown
by the dashed line, and the solid lines indicate the case where all tissues are insulin resistant
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Fig. 17 Postprandial kinetics for factional glucose oxidation (top left), adipose tissue TAG clearance (top
right) and P our AMP marker (lower left) for a balanced meal. The dashed lines show the response of a
healthy subject, and solid lines correspond to the case where all tissues are insulin resistant
Figure 17 shows the fraction ratio of oxidation due to glucose together with the
muscle concentration P (our marker for AMP) and adipose TAG clearance. In the case
of whole-body insulin resistance, there is less total oxidation and a smaller fraction
of glucose oxidation following the meal. Thus, insulin resistance causes reductions in
metabolic flexibility and in the total oxidation occurring, leading to an accumulation
of unused substrates in the muscle. The end result of this is a significant increase in
the time taken for the muscle to return to the fasting state; in fact, our simulations
show that even after 12h, the fasting state has not been recovered. There is also a
significant reduction in the amount TAG cleared from the plasma to adipose tissue,
which compensates for the increased TAG levels in the plasma and liver; this may lead
to non-alcoholic fatty liver disease.
3.5 Discussion
Comparing the results of all tissues being insulin resistant with the cases of just one
individual tissue, we can make several inferences. First, we note that left panels in
Fig. 14 have greater similarity with Fig. 10 than Figs. 2 or 6, suggesting that the
changes in plasma glucose and insulin are determined mainly by the insulin resistance
of the muscle rather than any insensitivity in the adipose or hepatic tissue. In contrast,
changes in the plasma FFA is more due to adipose tissue insensitivity rather than liver
or muscle. That plasma TAG shows little change between normal and all tissues being
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insulin resistant is due to some cancellation between the effects of insulin resistance
in the muscle and adipose tissue.
There is some cancellation of the effects of resistance of muscle and liver in liver
glycogen; see the top left panels of Figs. 7, 11 and 15. The lower left panels suggest that
the change in liver TAG is partly due to insulin resistance of the muscle, and change in
liver FFA is a combination of insulin resistance of adipose tissue and muscle as well
as the liver itself, and not just due to the liver being insulin resistant. The development
of a fatty liver is a complex process, and there will be other effects also, for example
the insulin-dependent activity of SREBP1c and Akt2 as noted by Shimomura et al.
(2000) and Wan et al. (2011).
All panels of Fig. 16 show similar effects to Fig. 12 (insulin-resistant muscle),
with some influence of adipose insensitivity on muscle FFA and muscle TAG (the
exception being the lower fasting concentration of muscle FFA caused by the insulin
resistance of adipose tissue). Similar comments can be made with regard to Figs. 17
and 13, where the effects of insulin resistance on P and relative glucose oxidation are
primarily due to muscle insensitivity rather than hepatic or adipose tissue, although
insulin resistance of adipose tissue has some influence of adipose TAG clearance.
4 Conclusions
In this paper, we extended a mathematical model of human metabolism, described in
detail in an earlier paper, in order to test the effects of insulin resistance on individual
tissues in the body. The motivation for this is to gain insight into the development
of diabetes and provide insight into the answers to questions such as “does insulin
resistance start in one tissue and spread to the others?” and “which tissue develops
insulin resistance first?”. We referred to the literature to parametrise our model for
insulin resistance and took account of the fact that tissues are affected by insulin
resistance to different degrees.
Our results show that when one tissue in the body is insulin resistant, reduced
metabolism causes increased levels of glucose and fats in plasma which affects other
tissues in the body. The largest effect is the liver becoming overloadedwith glucose and
rapidly reaching its maximum storage capacity when skeletal muscle is insulin resis-
tant. This leads to a double spike in plasma glucose, which causes the same behaviour
for plasma insulin, and affects the other components. However, in the situation where
all tissues are insulin resistant, we do not see the same results, as the liver glycogen
does not reach its maximum capacity, as its ability to take up glucose is itself impaired
by insulin resistance.
There are two plausible conclusions that can be drawn from this. The first is that
when the skeletal muscle is insulin resistant, the liver is overloaded, and over time,
this causes the liver to stop functioning normally and develop insulin resistance.
Another possibility is that, because the results for insulin-resistant skeletal muscle
have a strange double peak, they are unphysiological, and skeletal muscle is never, or
rarely, the first tissue to develop insulin resistance. However, the strange form is due
to the model having a sharp switch off of glucose transport into the liver when the
liver’s glycogen store reaches its maximum level. In reality, this switch off would be
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smoothed out by intermediate processes, and the minimum between the two maxima
(which in simulations is quite shallow and only lasts for a few minutes) would not be
observed in experiments. There is significant evidence that muscle is the first tissue to
become insulin resistant; see, for instance, DeFronzo and Tripathy (2009). However,
even if insulin resistance in one tissue causes resistance in another, the development
of insulin resistance in both tissues will be a gradual process. One would not expect
to simultaneously find the insulin sensitively of muscle severely compromised whilst
liver and adipose tissues were healthy. Tissues do not suddenly switch from normal
sensitivity, σ = 1, to resistant σ = 0.5 or 0.2 (see Table3 for sensitivities used here).
Instead, there will be a gradual reduction in σ values in all tissues concerned.
A further conclusion we can draw from our results is the effect of insulin resistance
on the fat content of the liver. It is still currently unknown whether a fatty liver is
the cause or an effect of insulin resistance. Our results have indicated that insulin
resistance can cause a net gain in liver fat, and this can occur when tissues other than
the liver were insulin resistant.
As described above, it seems that when one tissue is insulin resistant it causes the
others to become over-worked in order to compensate, which could lead to insulin
resistance also developing in these other tissues. Although hepatic insulin resistance
does not increase hepatic fat, once insulin resistance is developed in the whole body,
we see a rise in hepatic fat. Therefore, our results support the hypothesis that a fatty
liver is caused by insulin resistance; however, we are unable to test the converse with
our model, namely that fatty liver leads to insulin resistance.
We are also interested in the metabolic flexibility in skeletal muscle. Our results
show that when the liver or adipose tissue is insulin resistant there is little effect
on the percentage of oxidation due to glucose or on the total oxidation occurring.
However, in the case where skeletal muscle is insulin resistant there is a significant
decrease in metabolic flexibility (percentage of glucose oxidation), as well as in both
the preprandial percentage of glucose oxidation and the total amount of oxidation
both being reduced. These effects are seen to a greater extent when the whole body
is insulin resistant despite the fact that when only liver or adipose tissue was insulin
resistant it had only a slight effect.
Our results suggest that the liver develops insulin resistance earlier than muscle and
adipose tissue. This is seen from the increase in liver fat early in the process and is
consistent with observations of fatty liver in subjects of normal weight. Our analysis
which assumes one tissue is resistant whilst others have normal insulin sensitivity is
an oversimplification. In reality insulin resistance arises as a progressive deterioration.
Thus in the early stages, one would expect a small increase in fasting insulin, then
a small increase in fasting glucose and a larger increase in insulin and eventually a
rise in fasting triglycerides. Eventually, of course insulin release cannot keep up with
the resistance and insulin levels fall, glucose rises and diabetes occurs. To model the
early stages of IR, we have taken the increases in fasting insulin and glucose to be
negligibly small.
As the current model is focused on the response to a meal, one factor missing is
the effect on the fasting glucose level, which is raised in diabetes and prediabetes.
The reason for this is commonly thought to be due to hepatic insulin resistance; see,
for example, Bock et al. (2007). This effect could be accounted for in the model by
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incorporating the glucose sensitivity of the pancreas in the insulin production terms
in Eq. (1) and in reducing the rate at which insulin is broken down. The current work
Pratt et al. (2015a), Pratt et al. (2015b), Pratt (2015) focuses on improving themodel by
expanding it to give a more complete model of human metabolism by including more
intermediate stages the metabolic pathways, more transport terms (e.g. for pyruvate),
a more accurate description of insulin production, metabolism in adipose tissue and,
in addition to glucose, the input of fructose representing a non-insulin stimulating
carbohydrate.
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Appendix 1: Parametrising Insulin Resistance
In this appendix, we describe how we parametrise our model to describe the insulin
resistance in each of the tissues. This is achieved through the σX parameters (X =
A, AT, G, L , T,Y ), which are more accurately described as insulin sensitivities. We
take σX = 1 to represent normal sensitivity, and σX < 1 to indicate reduced sensitivity,
which is a measure of insulin resistance.
Hepatic Lipogenesis
Peterson et al. (2007) studied the effect of skeletal muscle insulin resistance on
metabolic syndrome. The study took a group of insulin-resistant subjects and a
group of insulin-sensitive subjects who, following an overnight fast, were fed two
test meals. Measurements were taken of liver and muscle glycogen and lipids. Of par-
ticular interest to us are the data comparing hepatic lipogenesis in insulin-resistant and
insulin-sensitive subjects. The results showed that approximately twice the amount of
lipogenesis occurred in the insulin-resistant subject compared to the insulin-sensitive.
The results also showed that plasma insulin levels in the insulin-resistant subjects were
approximately twice those of the insulin-sensitive. Hepatic lipogenesis is represented
in our model by the term kAL IGb/α in (3) and (7); in our model the increase in hepatic
lipogenesis can be entirely described by the difference in plasma insulin levels and no
extra parameter describing insulin sensitivity on this pathway is needed.
Hepatic Glucose Uptake and Hepatic Glucose Output
Krssak et al. (2004) have carried out a study into postprandial hepatic glycogen
metabolism in type 2 diabetes after both a mixed meal and a hyperglycaemic hyper-
insulinaemic clamp. Both sets of results are useful to us. During the clamp, the rate of
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hepatic glycogen storage in diabetic subjects was measured to be approximately 50%
that of the controls, with plasma insulin and glucose clamped at approximately the
same concentration in both controls and diabetic subjects. The rate of hepatic glycogen
storage is given in our model by the term σY kL IGb f2(YL)/η in (3) and (6), where
we have introduced the parameter σY to model insulin resistance. In order to achieve
a 50% reduced glycogen storage in insulin-resistant subjects we set σY = 0.5.
Of interest to us from the data for the mixed meal are the preprandial rates for
endogenous glucose production. The results for the diabetic subjects also showed
the production of approximately 2.0 mg/kg/min with a preprandial insulin level of
approximately 11 pmol/l, compared to the control subjects which showed a glucose
production rate of approximately 1.7mg/kg/min with a preprandial insulin level of
approximately 5pmol/l. The term in Eqs. (3) and (6) of our model that describes this
is given by βG f1(YL)/(α(1 + σLkGL I 2)) where we have introduced the parameter
σL to model the insulin sensitivity involved with hepatic glucose output. We choose
σL = 0.06 to fit our model to the results.
Hepatic TAG Output
Adiels et al. (2007) carried out a study into VLDL secretion rates. Their results showed
that, during the clamp, insulin-resistant subjects had an approximately 10% suppres-
sion of hepatic TAG output compared to a 50% suppression for the control subjects.
At the same time, the plasma insulin levels during the clamp were measured at 600
pmol/L for the insulin resistant and 500 pmol/L for the controls and before the clamp
at 100 pmol/L for insulin resistant and 50 pmol/L for the controls. We denote our para-
meter for hepatic TAG insulin sensitivity by σT , and the term in our model describing
hepatic TAG output is βT /(α(1+ σT kT L I )) in Eqs. (4) and (8). If we choose σT such
that the hepatic TAG output during the clamp is 90% of what it was before the clamp,
we obtain a value of σT ≈ 0.25.
Adipose Tissue FFA Output and TAG Uptake
Bickerton et al. (2008) carried out a study into adipose tissue fatty acid metabolism in
insulin-resistant and healthy subjects. The study commenced after an overnight fast
followed by a meal of equal amounts of fat and carbohydrates (40 grams of each).
Blood samples were taken before and for 6h after the meal and rates of uptake into
adipose tissue calculated. The first data of use to us from this paper are those for
adipose tissue NEFA (FFA) output. Preprandial adipose FFA output was measured
at approximately 600nmol/min/100g adipose tissue in the insulin-resistant subjects
compared to approximately 1200nmol/min/100g tissue in the controls, whilst post-
prandial output was measured at approximately 200nmol/min/100g tissue in both
the insulin-resistant and control subjects. Plasma insulin was measured at 50pmol/L
preprandial and 200pmol/L postprandial for the controls and 100pmol/L preprandial
and 350pmol/L postprandial for the insulin-resistant subjects.
To model the insulin sensitivity of FFA output from adipose tissue, we need to take
account of two effects noted by Bickerton et al. (2008). First, there is decreased output
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of FFA from adipose tissue in the fasting state. Second, whilst raised insulin levels
cause a decrease in FFA output, this decrease is reduced by insulin resistance. Thus,
we introduce two insulin sensitivities σA and φA and modify the output term from
βA/(α(1 + kAA I 2)) to φAβA/(α(1 + σAkAA I 2)). We set φA so that the preprandial
adipose FFA output in insulin-resistant subjects is half that of the controls. This yields
a value of φA ≈ 0.4. We set σA, which premultiplies I 2, to σA ≈ 0.1, so that the
change in plasma insulin for insulin-resistant subjects causes the output of FFA from
the adipose tissue to be reduced to one-third of its preprandial level.
The paper also has useful data on adipose tissue TAG uptake. Over the 6-h post-
prandial period, the rate of uptake for the insulin-resistant subjects is approximately
half that of the control subjects. We also note that the postprandial reduction in adi-
pose TAG clearance is about 50% in both the insulin-resistant and control subjects,
although the insulin-resistant group have a higher plasma insulin concentration. If
we take a similar approach to that adopted for adipose NEFA output and introduce
two parameters to model insulin resistance then the term in our model for adipose
TAG uptake in Eq. (4) is φAT kT A(1 + σAT kAI I )Tb. Now if we set φAT = φA = 0.4
and σAT = σA = 0.1 then our model achieves results that correspond to the above
experimental data.
Skeletal Muscle Glucose Uptake
Basu et al. (2007) carried out a study of glucose uptake in healthy and diabetic sub-
jects. They compared the muscle with splanchnic uptake, that is, by the visceral, or
abdominal organs. The study started after an overnight fast, and all subjects were given
a glucose infusion to maintain the arterial glucose concentration at approximately 9.3
mmol/l for both the control and diabetic subjects. All subjects were given a constant
insulin infusion at two rates, an initial low insulin infusion and later a high insulin infu-
sion. The resultant arterial insulin concentrations in the low insulin infusion subjects
was approximately 80 pmol/l in the diabetic subjects and approximately 70 pmol/l
in the controls; the high insulin infusion rates were approximately 170 pmol/l in the
diabetics and approximately 140 pmol/l in the control subjects.
The results of particular interest to us are those for leg glucose uptake during the
insulin infusions as we can take this as a guide for skeletal muscle glucose uptake. Leg
glucose uptake, during the low insulin infusion, was measured in diabetic subjects to
be three-fifths that of the controls (approximately 15 μmol/kg/min and approximately
25 μmol/kg/min, respectively), and during the high insulin infusion it was measured
in diabetics to be two-fifths of that in the controls (approximately 20µmol/kg/min
and approximately 50 μmol/kg/min, respectively, from Fig 4a of Basu et al. 2007).
The term in our model which describes skeletal muscle glucose uptake is given by
kG(1 + kGI IσG)Gb/α, where the parameter σG in Eqs. (3) and (10) describes the
insulin sensitivity. We choose σG such that the ratio between skeletal muscle glucose
uptake in healthy (σG = 1) and insulin-resistant simulations is the same as highlighted
in the experimental data. Using the values from the data for the low insulin infusion
gives a value of σG ≈ 0.2. We choose the data for the low insulin infusion rate as this
rate produces representative concentrations.
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Fig. 18 Postprandial kinetics for plasma glucose (top left), plasma insulin (bottom left), plasma FFA (top
right) and plasma TAG (bottom right) for a balanced meal, with adipose and muscle insulin resistance
(solid line), hepatic and muscle insulin resistance (dashed line), and adipose and liver insulin resistance
(dash-dotted line)
Appendix 2: Analysis of Insulin Resistance of Pairs of Tissues
In this appendix, we show the results of our model when two tissues are insulin
resistant. We thus consider the cases liver and adipose tissue resistant, adipose tissue
and skeletal muscle resistant, and the liver and the muscle tissue resistant. As before
we have simulated a healthy balanced meal ingested following an overnight fast and
we start with the results for plasma concentrations shown in Fig. 18.
By comparing the results in Fig. 18 with those presented in Fig. 2, we see that no
combination of two tissues being insulin resistant produces a large change in the results
for plasma FFA and TAG. Also we see that an insulin-resistant liver and adipose tissue
also have only a small effect on plasma glucose and insulin. Of particular interest
are the results for an insulin-resistant liver and muscle where the combination of both
tissues being resistant does not allow for the liver glycogen store to fill and, rather than
producing the dual peak results that we saw in Sect. 3.3 (and here with resistant muscle
and adipose tissue), we instead have the highest plasma glucose concentrations, with
the knock-on effect of higher plasma insulin.
We now consider the results for the liver shown in Fig. 19 which show that when
both the muscle and adipose tissue are insulin resistant then the hepatic glycogen store
is again saturated due to the decrease in muscle glucose clearance from the blood. In
both cases in which the liver is insulin resistant, there is a net loss of hepatic glycogen
and TAG over the 12- to 14-h period althoughwhen the skeletal muscle is also resistant
the increased plasma glucose levels result in slightly higher hepatic glycogen and TAG
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Fig. 19 Postprandial kinetics for liver glycogen (top left), liver TAG (bottom) and liver FFA (top right)
for a balanced meal, with adipose and muscle insulin resistance (solid line), hepatic and muscle insulin
resistance (dashed line), and adipose and liver insulin resistance (dash-dotted line)
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Fig. 20 Postprandial kinetics for muscle glucose (top left), muscle glycogen (bottom left), muscle FFA
(top right) and muscle TAG (bottom right) for a balanced meal, with adipose and muscle insulin resistance
(solid line), hepatic and muscle insulin resistance (dashed line), and adipose and liver insulin resistance
(dash-dotted line)
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Fig. 21 Postprandial kinetics for fractional glucose oxidation (upper left), adipose tissue TAG uptake
(upper right) and muscle P, our marker of AMP (lower left), following a balanced meal. Key: adipose and
muscle insulin resistance (solid line), hepatic and muscle insulin resistance (dashed line) and adipose and
liver insulin resistance (dash-dotted line)
levels. The results for insulin-resistant liver and adipose tissue are very similar to those
for where only the liver is insulin resistant.
Turning to the predicted concentrations in the muscle shown in Fig. 20, we observe
that any combination of insulin resistance in tissues does not produce a large difference
in the initial peaks of muscle glucose or glycogen. However, when the muscle is
insulin resistant the timescale over which steady state is reestablished is longer due
to a decrease in total muscle oxidation, as shown by the results for fractional glucose
oxidation and P , as shown in Fig. 21. We also see that insulin resistance of adipose
tissue results in lower levels of fasting muscle FFA and a suppression of the normal
reduction of muscle TAG following a meal.
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